Home Multimedia Exclusive Videos Exclusive VideosMultimedia ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients Sunday, January 1, 2017 Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit FLT3 in relapsed/refractory AML patients. Advertisement Recent Articles Is there a genetic risk for familial CLL? Tuesday, April 23, 2019 This month, Kanti R. Rai, MD, discusses familial chronic lymphocytic leukemia. And don't forget to check out next month's clinical dilemma - send in your... Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL Tuesday, April 23, 2019 Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and... Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more Tuesday, April 23, 2019 Remembering Arthur Rosenberg (1935 – 2018) Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed... Pulling Back the Curtain: Clara Bloomfield, MD Tuesday, April 23, 2019 In this edition, Clara Bloomfield, MD, talks about being on the right project at the right time and having academia in her blood.Where did... Raising the Barre: Kimberly Stegmaier, MD Tuesday, April 23, 2019 In this edition, Kimberly Stegmaier, MD, discusses her passion for ballet.What was your first experience with ballet? I grew up in Long Island and my... Current Issue April 2019, Volume 5, Issue 5 Monday, April 1, 2019 This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.